DNAprint Genomics (DNAG)

[mingwan0]

Some detail on the last project

http://www.cancer.mgh.harvard.edu/cancer_specialist_seiden.htm

http://www.genitrix.com/Website-PR%2010-15-03.html

Dr. Seiden serves as Chairman of the MGH Cancer Center Clinical Protocol Committee, as well as Chairman of the Dana Farber-Harvard Gynecologic Oncology Research Committee. He has published over 50 research articles and currently serves as Principal Investigator on 16 clinical and basic research projects. Dr. Seiden's administrative appointments have included Deputy Chief of Hematology/Oncology at MGH, Clinical Director of the MGH Center for Cancer Risk Analysis, Chairman of the Dana Farber Ovarian Carcinoma Immunotherapy Committee, and Director of the MGH/Brigham and Women's Oncology Fellowship Program. He serves as Assistant Professor of Medicine at Harvard Medical School. Dr. Seiden received his M.D. and Ph.D. degrees from Washington University, served as Chief Resident in Medicine at MGH, and completed fellowships at Dana Farber and the Brigham and Women's Hospital.

http://www.mgh.harvard.edu/pathology/pathology_services_SURGICAL_obstetric.htm

Dr. Esther Oliva has been appointed as a key co-investigator for an R01 NCI (R01-CA89150-01) (3 years) grant entitled “Identification of taxol resistance genes” collaborating with the Cancer Center, a consortium between the Massachusetts General Hospital, Dana Farber Cancer Institute and Brigham and Women’s Hospital, Dr. Michael Seiden being the principal investigator. In that study they are evaluating the potential role of the multi-drug resistance protein (MDAR-1) and other molecules known to be associated with drug resistance in predicting the clinical response of women with ovarian cancer to chemotherapy. They are studying paired tumor samples obtained from our tumor bank (Expression of multidrug resistance-1 (MDR-1) correlates with plalitaxel response in ovarian cancer patients. Penson RT, Oliva E, Skates SJ, Glyptis T, Fuller AF, Goodman AK, Nikrui N, Seiden MV. Cancer , in press.

From PubMed:

Duan Z, Duan Y, Lamendola DE, Yusuf RZ, Naeem R, Penson RT, Seiden MV. Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin Cancer Res. 2003 Jul;9(7):2778-85.

Lamendola DE, Duan Z, Yusuf RZ, Seiden MV. Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line. Cancer Res. 2003 May 1;63(9):2200-5.

Lamendola DE, Duan Z, Penson RT, Oliva E, Seiden MV. Beta tubulin mutations are rare in human ovarian carcinoma. Anticancer Res. 2003 Jan-Feb;23(1B):681-6.

Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets. 2003 Feb;3(1):1-19. Review.

Seiden MV, Swenerton KD, Matulonis U, Campos S, Rose P, Batist G, Ette E, Garg V, Fuller A, Harding MW, Charpentier D. A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol. 2002 Sep;86(3):302-10.

Duan Z, Lamendola DE, Yusuf RZ, Penson RT, Preffer FI, Seiden MV. Overexpression of human phosphoglycerate kinase 1 (PGK1) induces a multidrug resistance phenotype. Anticancer Res. 2002 Jul-Aug;22(4):1933-41.

Duan Z, Lamendola DE, Penson RT, Kronish KM, Seiden MV. Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells. Cytokine. 2002 Mar 7;17(5):234-42.

Penson RT, Kronish K, Duan Z, Feller AJ, Stark P, Cook SE, Duska LR, Fuller AF, Goodman AK, Nikrui N, MacNeill KM, Matulonis UA, Preffer FI, Seiden MV. Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer. 2000 Jan;10(1):33-41.

Duan Z, Feller AJ, Penson RT, Chabner BA, Seiden MV. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res. 1999 Nov;5(11):3445-53.

Duan Z, Feller AJ, Toh HC, Makastorsis T, Seiden MV. TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line. Gene. 1999 Mar 18;229(1-2):75-81.